Related Experiment Video
Updated: Jul 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy]
Argimiro Collado Serra1, Eduardo Solsona Narbón
1Servicio de Urología, Instituto Valenciano de Oncología (IVO), Valencia, España. argimirocollado@usa.net
Abstract:
Prostate cancer is one of the main health problems of the male population. Radical prostatectomy has demonstrated to have an excellent long-term cure rate. Nevertheless, globally, a 25% of the operated patients will suffer a PSA increase over 15 years of follow-up. Generally, the PSA value associated with a higher risk of clinical progression, that may be established as the cut point for biochemical recurrence is 0.4 ng/ ml. Once biochemical recurrence is diagnosed, the most important clinical data is to determine if clinical recurrence is going to be local or systemic, because it will determine treatment. Main parameters helping to differentiate between one and another are: time interval to PSA increase, PSA velocity, PSA doubling time (PSA-DT), pathologic stage and specimen's Gleason's score. The possibilities of treatment of biochemical failure after radical prostatectomy are under debate. Nevertheless, it is currently considered that patients with biochemical recurrence without radiological evidence of distant metastases are ideal candidates for local treatment with radiotherapy.
